SCHEMBL9747842

SCHEMBL9747842

C=C(c1ccc2c(c1)C(C)(C)CCC2(C)C)c1ccc2cc(C(=O)O)ccc2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARB P10826 14/20 1.00
RARG P13631 13/20 1.00
RARA P10276 12/20 1.00
RXRA P19793 8/20 0.81
RXRB P28702 7/20 0.81
RXRG P48443 5/20 0.81
CYP26A1 O43174 4/20 0.79
CYP26B1 Q9NR63 4/20 0.79
MEN1 O00255 1/20 0.57
ABCB11 O95342 1/20 0.57
ESR1 P03372 1/20 0.57
PGR P06401 1/20 0.57
HTR1A P08908 1/20 0.57
ADRA2A P08913 1/20 0.57
ADORA3 P0DMS8 1/20 0.57
CHRM1 P11229 1/20 0.57
DRD1 P21728 1/20 0.57
TBXA2R P21731 1/20 0.57
SLC6A2 P23975 1/20 0.57
ADRA1A P35348 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6818089 0.90 RXRA (1.00) RARBRARGRARARXRARXRB
SCHEMBL7756675 0.89 RARB (0.81) RARBRARGRARARXRARXRB
SCHEMBL2391376 0.88 RARB (1.00) RARBRARGRARARXRARXRB
SCHEMBL29827631 0.86 RARB (0.81) RARBRARGRARARXRARXRB
SCHEMBL846110 0.86 RARB (0.81) RARBRARGRARARXRARXRB
SCHEMBL9746786 0.85 RARB (0.74) RARBRARGRARARXRARXRB
Hydrochloric Acid SCHEMBL9120757 0.85 RARB (0.78) RARBRARGRARARXRARXRB
SCHEMBL2331952 0.84 RARB (1.00) RARBRARGRARARXRARXRB
SCHEMBL5712098 0.83 RARB (0.75) RARBRARGRARARXRARXRB
SCHEMBL5712126 0.83 RARB (0.75) RARBRARGRARARXRARXRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0220118-B1 BICYCLIC NAPHTHALENIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN HUMAN AND VETERINARY MEDICINE AND COSMETICS CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA - CIRD GALDERMA (FR) 1992-01-02 EP claimed
US-7449495-B2 Retinoid derivatives with antiangiogenic, antitumoral and proapoptotic activities SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2008-11-11 US disclosed
US-20080021088-A1 Retinoid Derivatives With Antiangiogenic, Antitumoral And Proapoptotic Activities SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2008-01-24 US disclosed
US-4826969-A SKIN AND EYE DISORDERS CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES C.I.R.D. (FR) 1989-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021088-A1 Retinoid Derivatives With Antiangiogenic, Antitumoral And Proapoptotic Activities RARA, RARB, RXRA RARB 2/4885RARG 4/4885RARA 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.